Use of Anti-Inflammatory Drugs and Lower Esophageal Sphincter-Relaxing Drugs and Risk of Esophageal and Gastric Cancers

Clinical Gastroenterology and Hepatology

Volumn 5, Issue 10, 2007, Pages

  Fortuny, Joan ^a,b   Johnson, Christine C ^c   Bohlke, Kari ^d   Chow, Wong Ho ^e   Hart, Gene ^d   Kucera, Gena ^c   Mujumdar, Urvi ^a   Ownby, Dennis ^f   Wells, Karen ^c   Yood, Marianne Ulcickas ^c,g   Engel, Lawrence S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOPHYLLINE; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; NITRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CARDIA CARCINOMA; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; PHARMACY; PRESCRIPTION; RISK REDUCTION; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TREATMENT RESPONSE;

EID: 34748847696     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.05.022     Document Type: Article

References (28)

1. Devesa S.S., Blot W.J., and Fraumeni Jr. J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
2. Enzinger P.C., and Mayer R.J. Esophageal cancer. N Engl J Med 349 (2003) 2241-2252
3. Lindblad M., Garcia Rodriguez L.A., and Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control 16 (2006) 285-294
4. Chow W.H., Blot W.J., Vaughan T.L., et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 90 (1998) 150-152
5. Chang J.T., and Katzka D.A. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med 164 (2004) 1482-1488
6. Lagergren J., Bergstrom R., Adami H.O., et al. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 133 (2000) 165-175
7. Vaughan T.L., Farrow D.C., Hansten P.D., et al. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev 7 (1998) 749-756
8. Chow W.H., Finkle W.D., McLaughlin J.K., et al. The relation of gstroesophageal reflux disease and its tretment to adenocarcinomas of the esophagus and gastric cardia. JAMA 274 (1995) 474-477
9. Wu A.H., Wan P., and Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control 12 (2001) 721-732
10. Corley D.A., Kerlikowske K., Verma R., et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124 (2003) 47-56
11. Farrow D.C., Vaughan T.L., Hansten P.D., et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 7 (1998) 97-102
12. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 15 (2006) 291-303
13. Farrow D.C., Vaughan T.L., Sweeney C., et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 11 (2000) 231-238
14. Gammon M.D., Schoenberg J.B., Ahsan H., et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 89 (1997) 1277-1284
15. Sorensen H.T., Mellemkjaer L., Friis S., et al. Use of systemic corticosteroids and risk of esophageal cancer. Epidemiology 13 (2002) 240
16. Bandi N., Ayalasomayajula S.P., Dhanda D.S., et al. Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model. J Pharm Pharmacol 57 (2005) 851-860
17. Lindblad M., Lagergren J., and Garcia Rodriguez L.A. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 444-450
18. Limburg P.J., Wei W., Ahnen D.J., et al. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology 129 (2005) 863-873
19. Wang W.H., Huang J.Q., Zheng G.F., et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 95 (2003) 1784-1791
20. Stack E., and DuBois R.N. Role of cyclooxygenase inhibitors for the prevention of colorectal cancer. Gastroenterol Clin North Am 30 (2001) 1001-1010
21. Strate L.L., and Syngal S. Hereditary colorectal cancer syndromes. Cancer Causes Control 16 (2005) 201-213
22. Wang H.H., Hsieh C.C., and Antonioli D.A. Rising incidence rate of esophageal adenocarcinoma and use of pharmaceutical agents that relax the lower esophageal sphincter (United States). Cancer Causes Control 5 (1994) 573-578
23. Guerra S., Sherrill D.L., Bobadilla A., et al. The relation of body mass index to asthma, chronic bronchitis, and enphysema. Chest 122 (2002) 1256-1263
24. Vaughan T.L., Dong L.M., Blount P.L., et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 6 (2005) 945-952
25. Rothman K.J., and Greenland S. Modern epidemiology. 2nd ed. (1998), Lippincott-Raven, Philadelphia
26. Fishman P., Taplin S., Meyer D., et al. Cost effectiveness of strategies to enhance mammography use. Eff Clin Pract 3 (2000) 213-220
27. Wagner E.H., Greene S.M., Hart G., et al. Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr 35 (2005) 3-11
28. Boudreau D.M., Doescher M.P., Jackson J.E., et al. Impact of healthcare delivery system on where HMO-enrolled seniors purchase medications. Ann Pharmacother 38 (2004) 1318-1319